Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business
incubator with a specific emphasis on disruptive cancer treatments, announced
today the company has retained The
Cervelle Group, a nationally known investor relations and public relations
firm to manage the company's communications program with shareholders and the
media. Cancer Therapeutics is compensating The Cervelle Group 75,000 shares
of restricted common stock for the three (3) months of service.
The Cervelle Group (www.thecervellegroup.com), based in Orlando, FL, will
focus on communicating with shareholders, prospective investors and the media
concerning Cancer Therapeutics. They will also assist with the dispensing of
information on the Company as well as its growth strategy and broadening the
"Medicine and treatments for a variety of diseases and ailments are continuing
to advance at a record pace, we believe the idea of what Cancer Therapeutics
is based on is not only a valid story but is a real company with tremendous
potential," said Rob M. Karbowsky, President of the Cervelle Group LLC.
"Cervelle specializes in working with undiscovered companies who have solid
management, a great story to tell and a significant upside for revenue generation
-- CTHP has these characteristics."